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Abstract
 
Bcr-Abl–expressing leukemic cells are highly resistant to apoptosis induced by chemotherapeu-
tic drugs. Although a number of signaling molecules have been shown to be activated by the
Bcr-Abl kinase, the antiapoptotic pathway triggered by this oncogene has not been elucidated.
Here, we show that the interleukin 3-independent expression of the antiapoptotic protein,
 
Bcl-x
 
L
 
, is induced by Bcr-Abl through activation of signal transducer and activator of transcrip-
tion (Stat)5. Inhibition of the Bcr-Abl kinase activity in Bcr-Abl–expressing cell lines and
 
CD34
 
1
 
 cells from chronic myelogenous leukemia (CML) patients induces apoptosis by sup-
pressing the capacity of Stat5 to interact with the bcl-x promoter. Interestingly, after inhibition
of the Bcr-Abl kinase, the expression of Bcl-x
 
L
 
 is downregulated more rapidly in chronic phase
than in blast crisis CML cells, suggesting an involvement of this protein in disease progression.
Overall, we describe a novel antiapoptotic pathway triggered by Bcr-Abl that may contribute
to the resistance of CML cells to undergo apoptosis.
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Introduction
 
Chronic myelogenous leukemia (CML)
 
1
 
 is characterized by
the reciprocal chromosomal translocation 9:22, which gen-
erates the Philadelphia chromosome (1). This event occurs
in a hematopoietic stem cell and fuses a truncated bcr gene
on chromosome 22 to sequences upstream of the second
exon of c-abl on chromosome 9. This translocation gener-
ates a novel fusion gene, bcr-abl, that encodes a chimeric
protein, p210, with a hyperactive tyrosine kinase.
 
The observation that production of Bcr-Abl is the initiat-
ing event in CML has focused attention on the tyrosine
phosphorylation-dependent signaling events triggered by
this oncoprotein. Expression of Bcr-Abl in hematopoietic
cells induces resistance to apoptosis, growth factor indepen-
dence, alterations in cell–cell and cell–matrix interactions,
and leukemogenesis (2–5). This phenotype is associated
with enhanced expression/activation of several effectors,
such as Ras, Rac, Raf-1, phosphatidylinositol-3 kinase (PI-
 
3k), Akt, nuclear factor 
 
k
 
B, and signal transducers and acti-
vators of transcription (STATs) (6).
Bcr-Abl–expressing leukemic cells are highly resistant to
apoptotic cell death induced by chemotherapeutic drugs (7,
8). Previously, we have shown that a CML-derived cell
 
line, K562, overexpresses the antiapoptotic protein Bcl-x
 
L
 
,
but not Bcl-2, a closely related member of the same family
of apoptosis regulators (9). Furthermore, downregulation of
Bcl-x
 
L
 
 by treatment of K562 cells with differentiation in-
ducers is accompanied by activation of an apoptotic path-
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way, which is abrogated by the ectopic expression of Bcl-x
 
L
 
.
In addition, Bcr-Abl–transfected HL-60 cells express high
levels of Bcl-x
 
L
 
 and undetectable levels of Bcl-2 (10), an ex-
pression pattern similar to that shown in K562 cells. These
findings suggest that Bcl-x
 
L
 
 may contribute to the resistance
of Bcr-Abl–expressing cells to apoptosis. Recently, we and
others have shown that Bcl-x
 
L
 
 is induced by activation of a
Stat protein, mainly Stat1, Stat3, and Stat5 (11–15) by direct
binding to a consensus sequence in the bcl-x gene pro-
moter. Since these Stat proteins appear to be constitutively
activated in Bcr-Abl–expressing cells (16, 17), we raised the
question of whether the antiapoptotic effect of Bcr-Abl was
due to the transcriptional upregulation of Bcl-x
 
L
 
 by activa-
tion of a Stat protein. Here, we show that Bcr-Abl and in-
terleukin (IL)-3 transduce antiapoptotic signals through the
Stat5/Bcl-x
 
L
 
 pathway in CML cells. Moreover, inhibition
of the Bcr-Abl kinase activity blocks this antiapoptotic
pathway more rapidly in chronic phase than in blast crisis
CML cells. Thus, we describe a novel antiapoptotic tran-
scriptional pathway triggered by the Bcr-Abl kinase activity
that may be useful not only to understand the mechanisms
of resistance to chemotherapy-induced apoptosis and disease
progression in CML, but also to have new molecular targets
for antileukemic drug discovery.
 
Materials and Methods
 
Samples from CML Patients and Normal Donors. 
 
A total of
100–250 mL of heparinized steady state or mobilized peripheral
blood was obtained from patients with CML in blast crisis (
 
n
 
 5 
 
5)
or chronic phase (
 
n
 
 5 
 
5). Mobilized peripheral blood progenitors
were obtained from normal donors (
 
n
 
 5 
 
5) undergoing mobiliza-
tion for allogeneic peripheral blood progenitor cell transplanta-
tion with G-CSF at doses of 5 mg/kg/12 h subcutaneously. All
patients and normal donors signed informed consent according to
Guidelines from the Committee for the Protection of Human
Subjects at the University of Valencia. All patients were 100%
Philadelphia chromosome positive at direct cytogenetic analysis.
 
Cell Culture. 
 
The CML-derived K562 and K562–Bcl-x
 
L
 
 (9)
cell lines were maintained in RPMI 1640 medium (Seromed
Biochrom KG) supplemented with 10% FCS (Flow Laborato-
ries). Parental Mo7e, Mo7e-Neo, and Mo7e-p210 cell lines (3),
were grown in IMDM (GibcoBRL) supplemented with 20%
FCS and with (Mo7e and Mo7e-Neo) or without (Mo7e-p210)
5 ng/mL of recombinant human IL-3 (Immunex).
CD34
 
1
 
 cells were selected from the PBMC population by ei-
ther two passages over the MACS CD34 Isolation Kit (Miltenyi
Biotec) as previously described (18) or by a single passage using
the CliniMACS separation device (Miltenyi Biotec) according to
the manufacturer. After positive selection, the CD34
 
1
 
 popula-
tions (
 
.
 
95%) were cultured in IMDM containing 20% FCS.
Normal CD34
 
1
 
 cells, and in some experiments, CML cells, were
maintained in culture supplemented with recombinant human
IL-3 at a final concentration of 100 ng/mL.
When indicated, cells were treated with 2 
 
m
 
M CGP 57148
(19), developed and provided by Novartis Inc., or 40 
 
m
 
M tyr-
phostin AG 555 (CALBIOCHEM) for different time intervals,
and then analyzed. Viability and total cell counts were deter-
mined at various times by trypan blue exclusion and counting of
at least 200 cells from each individual culture.
 
Cell Transfection. 
 
K562 cells (3 
 
3
 
 10
 
6
 
) were transfected with
the pSFFV-Neo expression vector containing a truncated form of
Stat5 that lacks the COOH-terminal transactivation domain
(Stat5
 
D
 
750) and exerts a dominant negative effect (11). pSFFV-
Stat5
 
D
 
750 (3 
 
m
 
g) or the control pSFFV-Neo vector (3 
 
m
 
g) was
mixed with 12 
 
m
 
l of lipofectamine (GibcoBRL) and incubated
with the cells for 5 h in the absence of FCS. Then, fresh complete
medium was added to the culture and after 24 h of incubation,
cells were harvested and analyzed for expression of Stat5
 
D
 
750 and
Bcl-x
 
L
 
 proteins.
 
Analysis of Apoptotic Cells. 
 
Apoptosis was assessed by several
criteria. DNA content was quantified by cell cycle analysis as de-
scribed elsewhere (20), with slight modifications. Cells (10
 
6
 
) were
resuspended in the fluorochrome solution (0.1% sodium citrate,
0.01% Triton X-100, and 0.1 mg/mL propidium iodide). After
4 h at 4
 
8
 
C in the dark, fluorescence was measured using a FACScan
flow cytometer (Becton Dickinson). The percentage of hypodip-
loid cells correlates with the extent of apoptosis in the sample. For
DNA fragmentation analysis, cells (10
 
6
 
) were washed with PBS and
pelleted by centrifugation. Genomic DNA was isolated from cell
pellets as described previously (9). DNA samples were electropho-
resed on a 2% agarose gel and stained with 0.1% ethidium bromide.
The early apoptotic cells were detected with annexin V labeled with
fluorescein isothiocyanate (PharMingen) by flow cytometry.
 
Western Blot Analysis. 
 
The expression of Bcl-x
 
L
 
 protein was
determined by Western blotting as previously described (9). Pro-
teins (30–60 
 
m
 
g) were separated on a 12% polyacrylamide gel,
and transferred to nitrocellulose. Blots were blocked with 3%
BSA and incubated with rabbit antibodies against Bcl-x (Trans-
duction Laboratories), and mouse anti–
 
b
 
-tubulin (Sigma Chemi-
cal Co.), and then incubated with goat anti–rabbit or anti–mouse
antibodies conjugated to alkaline phosphatase (Tropix). Bound
antibody was detected by a chemiluminescence system (Tropix).
In some experiments, 3–8% NuPAGE Tris-Acetate gels (Novex)
were used to separate endogenous Stat5 from transfected
Stat5
 
D
 
750 proteins.
 
Immunoprecipitation. 
 
K562 and Mo7e-p210 cells were cul-
tured with or without tyrosine kinase inhibitors (CGP 57148 and
tyrphostin AG 555) for 3 h, and were then lysed in 0.5% NP-40–
containing solution as previously described (11). Cleared lysates
were incubated with mouse monoclonal anti–c-Abl, rabbit anti-
Stat5, anti-Stat1, or anti-Stat3 antibodies (Santa Cruz), and protein
A/G conjugated to agarose beads (Santa Cruz). Proteins eluted
from the agarose beads were electrophoresed and transferred to
nitrocellulose. Membranes were incubated with the same primary
antibodies used for immunoprecipitation or mouse antiphospho-
tyrosine (Upstate Biotechnology), and bound antibodies were de-
tected as described above.
 
Electrophoretic Mobility Shift Assays (EMSAs). 
 
Cells were cul-
tured for 3 h in the presence or absence of tyrosine kinase inhibi-
tors, and were then lysed as previously described (11). In brief,
nuclear fractions were resuspended in 20 mM Hepes, pH 7.6, 0.4
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 10
mM sodium molybdate, and protease inhibitors. Nuclear extracts
(5 
 
m
 
g of total protein) were incubated with a 
 
32
 
P-labeled double-
stranded DNA probe from the promoter region of the bcl-x gene
(11) or from the SV40 enhancer, containing a single consensus se-
quence for Spi-1/PU.1 (21). Samples were run on a 5% nondena-
turing polyacrylamide gel in 200 mM Tris-borate and 2 mM
EDTA. Gels were dried and visualized by autoradiography. Su-
pershifts were performed using rabbit polyclonal antibodies spe-
cific for Stat5 (Santa Cruz) or Spi-1 (generously provided by Dr.
J. Leon, University of Cantabria, Spain). For competition assays, 
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nuclear extracts containing equal amounts of total protein were
preincubated with 100-fold molar excess of either unlabeled bcl-x
probe or unlabeled irrelevant DNA fragment.
 
Results
 
Bcr-Abl Upregulates Bcl-x
 
L 
 
through Activation of Stat5 in
K562 Cells. 
 
The activation of Stat5 may play an important
role in Bcr-Abl–mediated transformation and leukemogene-
sis (16); however, the biological consequences of this activa-
tion in hematopoietic cells are not elucidated. Recently, we
have shown that erythropoietin can induce the expression
of the antiapoptotic protein, Bcl-x
 
L
 
, through the binding of
Stat5 to the bcl-x promoter, which may contribute to
maintain the survival of erythoid progenitors (11). To study
whether this antiapoptotic pathway is activated by Bcr-Abl,
we treated K562 cells, which have endogenous expression
of p210 Bcr-Abl, with CGP 57148, an ATP-competitive
inhibitor of the Abl protein kinase that has been shown to
efficiently eradicate human CML-derived cells in a mouse
model (22). It has been described that a complete inhibition
of autophosphorylation of the Bcr-Abl kinase is achieved
with CGP 57148 at concentrations between 1 and 10 
 
m
 
M
(23). Based on this result, we treated K562 cells with differ-
ent concentrations of CGP 57148 (from 0.5–4 
 
m
 
M) for 3 h,
and found that 2 
 
m
 
M completely abrogated phosphoryla-
tion of Bcr-Abl, as assessed by antiphosphotyrosine immu-
noblots of anti–c-Abl-immunoprecipitated cell lysates (Fig. 1
and data not shown). In addition, at this concentration,
CGP 57148 inhibited phosphorylation of Stat5, whereas
Stat3 and Stat1 remained phosphorylated. By contrast, in
untreated cells or in cells treated for 3 h with 40 
 
m
 
M tyr-
phostin 555, an inhibitor selective for epidermal growth fac-
tor receptor kinase (24), immunoprecipitated Bcr-Abl, Stat5,
Stat1, and Stat3 were all phosphorylated (Fig. 1). Since the
expression of Stat proteins was the same at all culture condi-
tions, this finding suggests that the loss of Stat5 phosphory-
lation correlated with inhibition of the Bcr-Abl kinase ac-
tivity. Furthermore, the expression of Bcl-x
 
L
 
 in K562 cells
gradually decreased within 48 h of treatment with CGP
57148 (Fig. 2 A), and this correlated with the activation of
an apoptotic process, as assessed by cell cycle analysis (Fig.
2 B) and genomic DNA fragmentation analysis (data not
shown). After 24 h of treatment, the percentage of cells in
 
the sub-G1 peak of apoptotic cells increased from 14.8%
(9.2
 
 6 
 
3.3, mean
 
 6 
 
SD,
 
 n 
 
5 
 
3) to 38.9% (43.7
 
 6 
 
5.2) and
the G
 
2
 
/M fraction decreased from 27.2
 
 6 
 
3.3% to 11.6
 
 6
 
2.1%. In contrast, the fraction of K562 cells stably trans-
fected with Bcl-x
 
L
 
 (constitutive expression driven by the
SFFV promoter; 9) that appeared in the sub-G
 
1
 
 cycle phase
after 24 h of treatment with CGP 57148 was 11.9% (10.1
 
 6
 
2.6), compared with 5.7% (6.6
 
 6 
 
1.8) in untreated cells
(Fig. 2, A and B). However, the G
 
2
 
/M fraction was re-
duced in these transfected cells (from 28.7
 
 6 
 
3.8% to 13.1
 
 6
 
2.6%), indicating that a constitutive, Stat5 independent ex-
pression of Bcl-x
 
L
 
 blocked apoptosis induced by inhibition
of the Bcr-Abl kinase activity, but not proliferation. Be-
cause multiple signal transduction pathways have been
shown to be activated by Bcr-Abl (25), we next studied the
effects of a dominant negative Stat5 protein on Bcl-x
 
L
 
 ex-
pression and cell survival (a representative experiment is
shown in Fig. 3). A Stat5 protein that lacks the transactivation
domain and exerts a dominant negative effect (Stat5
 
D
 
750)
was transiently transfected in K562 cells. After 24 h of trans-
fection, the expression of Stat5 dominant negative correlated
with downregulation of Bcl-x
 
L
 
 (Fig. 3 A). Significantly,
when we examined transiently transfected Stat5
 
D
 
750-express-
ing cells by annexin V staining and FACS analysis, an in-
crease in the percentage of apoptotic cells (23.8%) was ob-
served relative to empty vector transfectants (5.2%; Fig. 3 B).
These results demonstrate that Stat5-dependent signaling is
required for preventing loss of Bcl-x
 
L
 
 expression and apop-
tosis in K562 cells.
Figure 1. Tyrosine phosphor-
ylation of Bcr-Abl and Stat pro-
teins in K562 cells. Cells were
cultured with CGP 57148 or
tyrphostin AG 555 for 3 h, and
then cell extracts were analyzed
by immunoprecipitation (IP) with
antibodies specific for c-Abl, Stat5,
Stat1, and Stat3, and by subse-
quent blotting with an antiphos-
photyrosine antibody (apY). The
same filters were stripped and re-
blotted with the same antibodies
used for IP. C, Untreated control
cells.
Figure 2. Analysis of Bcl-xL and apoptosis in K562 and K562–Bcl-xL
cell lines. (A) Cells were treated for different times with CGP 57148
and analyzed for the expression of Bcl-xL by Western blot. The levels of
b-tubulin were also analyzed to assure equal loading. (B) Apoptosis of
cells treated with the kinase inhibitor was quantified by cell cycle analysis.
Numbers represent the percentage of cells with subdiploid DNA content.
Histograms are from a representative experiment (n 5 3). 
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Blockade of the Bcr-Abl Kinase Inhibits the Stat5/Bcl-x
 
L
 
Antiapoptotic Pathway in Bcr-Abl–Transfected Cells. 
 
The ef-
fects of CGP 57148 on the inhibition of the Stat5/Bcl-x
 
L
 
antiapoptotic pathway were compared in IL-3–indepen-
dent Bcr-Abl–transfected Mo7e cells (Mo7e-p210) versus
the control IL-3–dependent Mo7e and Mo7e-Neo cells (3).
As shown in Fig. 4, CGP 57148 (2 
 
m
 
M) inhibited phos-
phorylation of Bcr-Abl and Stat5 in Mo7e-p210 cells,
whereas Stat3 and Stat1 remained phosphorylated, a result
similar to that obtained in K562 cells. In addition, after an
exposure to CGP 57148 for 3 h, complete inhibition of the
Stat5–DNA binding complex was observed in Mo7e-p210
cells, but not in Mo7e-Neo cells, as measured in EMSA us-
ing an oligonucleotide that corresponds to a consensus Stat5
sequence of the bcl-x promoter (Fig. 5). The specificity of
the Stat5 binding was confirmed using anti-Stat5 antibodies
that supershifted all of the DNA protein complexes in Mo7e-
p210 and Mo7e-Neo cells (Fig. 5). Furthermore, treatment
of cells with AG 555 or preincubation of the nuclear ex-
 
tracts with a 100-fold molar excess of a nonspecific probe
did not affect the Stat5-DNA binding; however, a 100-fold
molar excess of the unlabeled Stat5-specific probe inhibited
the formation of this complex in both cell populations. To
further control the specificity of the inhibitor, nuclear ex-
tracts from Mo7e-p210 cells were analyzed by EMSA with
a probe containing the binding site for Spi-1/PU.1, a tran-
scription factor of the Ets family, expressed in myeloid cells
(21). Fig. 5 shows that the protein–DNA binding complex
was detected both in controls (untreated cells or cells
treated with AG 555) and in cells treated with CGP 57148.
Next, we analyzed the levels of Bcl-x
 
L
 
 protein in the
different cell populations. As shown in Fig. 6, CGP 57148
inhibited the expression of Bcl-x
 
L
 
 and induced loss of cell
viability in Mo7e-p210, but not in parental Mo7e or
Mo7e-Neo cells. Treatment of Mo7e-p210 cells with
CGP 57148 for 24 h drastically reduced the expression of
Bcl-x
 
L
 
, which continued to decrease by 48 h of treatment
(Fig. 6 A). This pattern of expression correlated with the
progressive loss of Mo7e-p210 cell viability within five
days of treatment with the inhibitor (Fig. 6 B), due to the
activation of an apoptotic process as assessed by genomic
DNA fragmentation analysis (data not shown). Because
Mo7e cells become IL-3 independent upon transfection
with Bcr-Abl cDNA, and do not undergo apoptosis in the
absence of IL-3, we examined whether the antiapoptotic
pathway inhibited by CGP 57148 could be restored by
culturing Mo7e-p210 in the presence of IL-3. As shown
in Fig. 6, in the presence of IL-3, the Bcr-Abl kinase in-
hibitor did not affect the levels of Bcl-x
 
L
 
 within 48 h of
treatment, and this correlated with activation of Stat5 as
assessed by EMSA (data not shown). Furthermore, under
these culture conditions, cell viability was maintained by
the first three to four days, and it was slightly reduced by
the fifth day (64%), a time point to which most of the
Mo7e-p210 cells (90%) treated with CGP 57148 in the
Figure 3. Analysis of Bcl-xL and apoptosis in K562 cells transfected
with a Stat5 dominant negative. Cells were transiently transfected with
3 mg of pSFFV-Neo (control vector) or pSFFV-Stat5D750 (dominant
negative) and then analyzed. (A) Western blot analysis with a polyclonal
antibody that recognizes both Stat5 and Stat5D750 proteins, and with a
rabbit anti–Bcl-x antibody. The levels of b-tubulin were used as a loading
control. (B) Apoptosis of transfected cells, measured by staining with an-
nexin V-FITC and analysis by flow cytometry. Histograms are from a
representative experiment (n 5 3).
Figure 4. Tyrosine phosphory-
lation of Bcr-Abl and Stat proteins
in Mo7e-p210 cells. Cells were
cultured with CGP 57148 or tyr-
phostin AG 555 for 3 h, and then
cell extracts were analyzed by im-
munoprecipitation (IP) with anti-
bodies specific for c-Abl, Stat5,
Stat1, and Stat3, and by subse-
quent blotting with an antiphos-
photyrosine antibody (apY). The
same filters were stripped and re-
blotted with the same antibodies
used for IP. C, Untreated control
cells.
Figure 5. Binding of Stat5 to
the bcl-x promoter in Mo7e-Neo
and Mo7e-p210 cell lines. Cells
were treated for 3 h with CGP
57148 or tyrphostin AG 555, and
formation of Stat5-DNA com-
plexes was determined by an
EMSA using a radiolabeled bcl-x
probe. DNA binding activity of
Spi-1/PU.1 in Mo7e-p210 cells
was also analyzed as a specificity
control. Nuclear extracts from
untreated cells (C) were preincu-
bated with antibodies specific for
Stat5 (1anti-ST5) or Spi-1 (anti-
Spi1), and with an excess of an
unlabeled bcl-x probe as a specific
competitor (1SP) or with an irrel-
evant nonspecific probe (1non-
SP). Extracts from COS cells
transfected with a Spi-1 expression
vector (COS-Spi) were used as
positive controls.981 Horita et al.
absence of IL-3 were dead, suggesting that IL-3 and Bcr-
Abl may activate the same antiapoptotic pathway.
Inhibition of the Bcr-Abl Kinase Activity Downregulates the
Expression of Bcl-xL and Induces Apoptosis in CML Cells from
Patients in Chronic Phase and Blast Crisis.  To extend these
findings to a more clinically relevant cellular model, we
treated CD341 progenitor cells from normal donors and
patients with chronic phase CML and blast crisis CML
with CGP 57148. Treatment of blast crisis and chronic
phase CML cells with CGP 57148 for 3 h in the absence
of growth factors completely abrogated the binding of
Stat5 to the Stat5-specific sequence of the bcl-x promoter;
however, treatment with the control tyrosine kinase inhibi-
tor, AG 555, did not affect the formation of the Stat5-DNA
binding complex (Fig. 7 shows a representative experiment).
The specificity of the Stat5 binding was confirmed using
antibodies against Stat5. As shown in Fig. 7, all of the
DNA–protein complexes were supershifted by pretreat-
ment of nuclear extracts with the antibodies. This pattern
of Stat5 activation in CML primary cells thus, is similar to
that of Mo7e-p210 cells described above.
To define the antiapoptotic pathway in CML CD341 cells,
the expression of Bcl-xL and the percentage of viable
cells were compared in blast crisis and chronic phase CML
cells versus normal CD341 cells after treatment with CGP
57148 (Fig. 8). Normal cells, cultured in the presence of
IL-3, did not show any variation in the levels of Bcl-xL at
any time of treatment. In contrast, both chronic phase and
blast crisis CML cells showed a downregulated expression
of Bcl-xL (Fig. 8 A shows a representative experiment).
However, it is noteworthy that, whereas Bcl-xL protein
virtually disappeared in chronic phase within 24 h of
treatment, it was readily detectable, although at lower lev-
els, in blast crisis after 48 h of treatment with the kinase
inhibitor. This loss of Bcl-xL expression was restored in
the presence of IL-3 in both cell populations. Further-
more, this pattern of expression correlated with cell via-
bility. Viability of normal CD341 cells was maintained
during the treatment with CGP 57148. In contrast, CML
CD341 cells progressively died within four days of treat-
ment; however, as shown previously for Mo7e-p210, cell
Figure 6. Analysis of Bcl-xL and cell viability in Mo7e, Mo7e-Neo,
and Mo7e-p210 cell lines. Mo7e-p210 cells were treated for different
times with CGP 57148 or tyrphostin AG 555 in the presence or absence
of IL-3. Mo7e and Mo7e-Neo (Bcr-Abl2) cells were also incubated with
the inhibitors in the presence of IL-3. (A) At the indicated times, cells
were harvested and analyzed for the expression of Bcl-xL by Western blot.
The levels of b-tubulin were also analyzed to assure equal loading. C,
Untreated control cells. (B) Viability of the Mo7e cell lines was measured
by trypan blue dye exclusion at different times of incubation with CGP
57148. All data points represent the mean of triplicate cultures 6 SD.
Figure 7. Binding of Stat5 to
the bcl-x promoter in blast crisis
and chronic phase CML cells.
CD341 cells were isolated from
the peripheral blood of patients
with CML in blast crisis and
chronic phase, and treated for 3 h
with CGP 57148 or tyrphostin
AG 555. An EMSA was per-
formed using a radiolabeled bcl-x
probe. Nuclear extracts from un-
treated cells (C) were preincu-
bated with antibodies specific for
Stat5 (1anti-ST5), and with an
excess of an unlabeled bcl-x
probe as a specific competitor
(1SP) or with an irrelevant non-
specific probe (1non-SP).
Figure 8. Analysis of Bcl-xL and cell viability in chronic phase and blast
crisis CML cells. CD341 cells were isolated from the peripheral blood of
patients with CML in chronic phase or in blast crisis and treated with tyr-
phostin AG 555 or CGP 57148 in the presence or absence of IL-3. Nor-
mal CD341 cells were treated with the same inhibitors in the presence of
IL-3. (A) At the indicated times, cells were analyzed for the expression of
Bcl-xL by Western blot. The levels of b-tubulin were also analyzed to as-
sure equal loading. C, Untreated control cells. (B) Viability of normal and
CML cells was measured by trypan blue dye exclusion at different times
of incubation with CGP 57148. All data points represent the mean of
triplicate cultures 6 SD.982 Bcr-Abl Kinase Activates the Stat5/Bcl-xL Antiapoptotic Pathway
viability was restored by addition of IL-3 to the culture.
Consistent with the protein analysis data, blast crisis CML
cells died at a slower rate. By 24 h of treatment with the
inhibitor, viability of blast crisis cells decreased from 76%
(day 0) to 60%, whereas viability of chronic phase cells
was reduced from 65% (day 0) to 23% (Fig. 8 B).
Discussion
Evidence is emerging to support the idea that Bcr-Abl
exerts an antiapoptotic effect (8, 10, 20) that may contrib-
ute to the resistance of Bcr-Abl expressing cells to high
doses of antileukemic drugs such as Ara-C or etoposide
(26). However, the signaling pathway triggered by Bcr-Abl
to inhibit apoptosis has not been elucidated. Here, we have
shown that treatment of both Bcr-Abl–expressing cell lines
and CD341 CML cells with CGP 57148, a selective inhib-
itor of the Bcr-Abl kinase activity, blocks activation of
Stat5, a transcription factor recently shown to induce the
expression of Bcl-xL in response to erythropoietin and IL-3
in hematopoietic progenitors (11–13). Consistent with this,
we found that inactivation of Stat5 in CML-derived cells
by treatment with the kinase inhibitor or transfection with
a Stat5 dominant negative, downregulates the expression of
Bcl-xL and induces an apoptotic process. Stat5 activation
has been involved in antiapoptotic activity and cell cycle
progression induced by Bcr-Abl, and it has been suggested
that the constitutive activation of Stat5 is important for
Bcr-Abl–mediated leukemogenesis in vitro and in vivo
(16). Stat5 is phosphorylated on tyrosine residues in he-
matopoietic cells in response to growth factors such as IL-3,
IL-5, GM-CSF, and Epo (27, 28), and this may represent
an important point of convergence between the Bcr-Abl
and IL-3 signaling pathways that could contribute to the
known overlap in the biological effects of IL-3 and Bcr-Abl
(17). Consistent with this, we found that inhibition of the
Stat5/Bcl-xL antiapoptotic pathway by treatment of Bcr-
Abl–transfected Mo7e cells and CD341 CML cells with
CGP 57148 could be overcome in the presence of IL-3,
which induced activation of Stat5 and upregulated the ex-
pression of Bcl-xL. In addition, recently it has been shown
that IL-3 regulates the expression of Bcl-xL by Stat5 in a
bone marrow-derived cell line (13). These findings indicate
that IL-3 and Bcr-Abl are transducing survival signals through
the same pathway that involves activation of Stat5 and ex-
pression of Bcl-xL. Nevertheless, since it has been shown
that Bcl-xL can be phosphorylated in some cell systems (29)
we cannot rule out the possibility that Bcr-Abl may also
mediate phosphorylation of Bcl-xL, which could play a role
in modulating Bcl-xL function.
CML is characterized by a stable phase in which the ex-
panded myeloid population undergo complete differentia-
tion and a blast crisis or accelerated phase that follows the
chronic phase, in which the myeloid cells are unable to dif-
ferentiate, resulting in an acute leukemia. Although chromo-
somal alterations other than the t(9;22) translocation are de-
tected in blast crisis CML cells, a specific molecular marker
of this phase of the disease has not been characterized yet. In
this study, we have shown that the expression of Bcl-xL is in-
hibited at earlier times in chronic phase than in blast crisis
CML cells after blockade the Bcr-Abl kinase activity, and
this correlates with a more rapid loss of cell viability. This
finding suggests that additional genetic abnormalities may
contribute to the resistance of blast crisis CML cells to un-
dergo apoptosis. Recently, the biological effects of high and
low levels of Bcr-Abl expression have been compared in
growth factor-dependent myeloid cells, demonstrating that,
although low levels of Bcr-Abl were sufficient to render
these cell lines growth factor independent and tumorigenic,
higher levels were mandatory for additional protection
against apoptosis (30). According to this, a prolonged expres-
sion of Bcl-xL could be due to increased levels of Bcr-Abl,
which is consistent with the evidence that the expression of
bcr-abl mRNA frequently increases with disease progression
and that the duplication of the Philadelphia chromosome
represents the most frequent karyotypic abnormality in blast
crisis CML (31, 32). Alternatively, activation of Stat proteins
other than Stat5 could contribute to prolong the expression
of Bcl-xL in blast crisis, although it would not be sufficient to
maintain the levels of this antiapoptotic protein. It has been
shown that most of the Bcr-Abl–induced Stat activity is due
to Stat5 (16, this paper); however, Stat1 and Stat3 are also ac-
tivated in hematopoietic cell lines expressing Bcr-Abl and in
CML cells (33). Stat1 and Stat3 are able to bind the bcl-x
promoter and to induce transactivation of this gene in cardiac
myocytes (14), and myeloma cells (15), respectively. Conse-
quently, an increased phosphorylation of at least one of these
Stat family members could extend cell survival in blast crisis
CML cells. A third possibility is that prolonged expression of
Bcl-xL is due to an increase in the Bcl-xL protein half-life. In
line with this, it has been described that the decreased protein
levels of Bcl-xL in a T cell clone after growth factor with-
drawal is due to the cleavage of Bcl-xL by caspase-3, which
results in accelerated apoptotic cell death (34). Thus, inhibi-
tion of this enzymatic activity could account for an increased
Bcl-xL protein half-life in blast crisis CML cells.
In conclusion, we have described a novel Bcr-Abl–
induced antiapoptotic pathway in CML cells that may con-
tribute to malignant progression by conferring a survival
advantage through suppression of apoptotic cell death. Fur-
thermore, this pathway, which induces expression of Bcl-xL
by activation of Stat5, represents an attractive target for
drug discovery with the potential of inducing cell death of
human leukemic cells.
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